| Name | Title | Contact Details |
|---|
Goldfinch Bio is a biotechnology company that is singularly focused on discovering and developing precision therapies for kidney disease. Just as the goldfinch was a prominent figure of the Renaissance, Goldfinch Bio is leading a new age of therapeutic discovery to transform the treatment paradigm for patients with kidney disease. Goldfinch is integrating breakthroughs in kidney genetics and biology to identify new therapeutic targets and advance first-in-class drug candidates to treat patients with kidney disease. Our Product Engine will industrialize the integration of genetics and kidney biology and confer a differentiated ability to identify, validate, and pursue novel therapeutic targets to treat progressive kidney disease. At Goldfinch, we`re pioneering a new approach to discover and develop therapeutics that target the molecular basis of kidney disease. We`re looking for teammates who relish the challenge, and are compelled to leave a positive mark on the lives of colleagues and patients alike.
Myovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women`s health diseases and other endocrine-related disorders. Myovant`s lead product candidate is relugolix, an oral, once-daily, small molecule that acts as a GnRH receptor antagonist. Myovant is in the process of initiating five international Phase 3 clinical trials for relugolix, two in women with heavy menstrual bleeding associated with uterine fibroids, two in women with endometriosis-associated pain, and one in men with advanced prostate cancer. Myovant is simultaneously developing MVT-602, an analog of kisspeptin, for the treatment of female infertility as part of assisted reproduction. Over time, the company intends to expand its development pipeline to include other potential treatments for women`s health and endocrine-related disorders.
Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets. Our 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. Our lead programs address diseases from inflammatory disorders to oncology. SNA constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. SNA constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. Moreover, SNAs can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease.
CardioVascular BioTherapeutics, Inc. is a Las Vegas, NV-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Developing new treatments for rare and orphan neurological conditions.